YZi Labs announces investment in regenerative medicine company Renewal Bio
Jinse Finance reported that YZi Labs has announced an investment in the regenerative medicine company Renewal Bio, marking YZi Labs' first biotechnology investment since expanding its investment scope in early 2025. Renewal Bio focuses on using its proprietary Stembroid™ platform to generate DNA-matched human cells and tissues from patients' own cells, aiming to address the global organ shortage crisis. This round of funding will accelerate the preclinical development of Stembroid-derived hematopoietic stem cells for the treatment of leukemia and immune diseases, and support the expansion of laboratory infrastructure.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks
Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.
Crypto prices
More
